Effect of Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases. A Single-centre Cohort Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 170
- Primary Endpoint
- Survival
Study Overview
Brief Summary
Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates and patterns of recurrence following liver resections for CRLM and concurrently, characterise clinical, pathological and treatment-related factors that could function as predictors of recurrence or survival, particularly neoadjuvant chemotherapy and tumour clearance.
Detailed Description
This is a descriptive, observational study with retrospective analysis of a prospectively collated database. This database included all patients who underwent curative hepatic resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital (Adelaide, Australia) between December 2004 and October 2020.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who underwent a liver resection for CRLM at The Queen Elizabeth Hospital between December 2004 to September 2020
Exclusion Criteria
- •Patients whose procedures were abandoned due to unresectable tumour burden
Outcomes
Primary Outcomes
Survival
Time Frame: From surgery to death or end of the study, up to 16 years
up to16 years
Recurrence
Time Frame: From surgery to recurrence, up to 16 years
Recurrence rate
Secondary Outcomes
- Resection margins(From surgery to death or end of the study, up to 16 years)
- Neoadjuvant Chemotherapy(From surgery to death or end of the study, up to 16 years)
Investigators
Mauro Andres Perdomo, MD, MHA
MD, General Surgeon
Hospital Maciel